Millennium Withdraws Velcade Follicular Lymphoma sNDA, Citing Business Decision
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will continue to evaluate bortezomib in follicular lymphoma subgroups as part of its larger development program for the first-in-class proteasome inhibitor.